AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement
This article was originally published in The Rose Sheet
Executive Summary
FDA regulation of kratom as an NDI is necessary to avoid untenable state regulations, says AHPA chief Michael McGuffin, adding the trade group's support to kratom experts' push to keep the herbal ingredient available. Experts also say salmonella issues currently linked to kratom could be an indirect result of FDA's import alert as noncompliant suppliers filled continued demand.